Clene, Inc.’s CNM-Au8 for amyotrophic lateral sclerosis has missed the mark in a Phase II/III trial but positive data in a secondary survival endpoint could help pave the way to market, given recent approvals in the space.
The investigator-initiated Healey ALS Platform trial randomized 161 patients to 30mg or 60mg CNM-Au8 or placebo with standard of care for 24 weeks. CNM-Au8 missed the primary endpoint of slope of change in ALS Functional Rating Scale Revised scores adjusted for mortality according to topline data
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?